共 51 条
[1]
Sprague BL(2009)Prevalence of breast carcinoma in situ in the United States JAMA 302 846-848
[2]
Trentham-Dietz A(2006)Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988–2001 Cancer 106 2104-2112
[3]
Li CI(2003)The risk of a contralateral breast cancer among women diagnosed with ductal and lobular breast carcinoma in situ: data from the Connecticut tumor registry Breast 12 451-456
[4]
Malone KE(2015)RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation J Clin Oncol 33 709-715
[5]
Saltzman BS(1999)Tamoxifen in treatment of intraductal breast cancer: national surgical adjuvant breast and bowel project B-24 randomised controlled trial Lancet 353 1993-2000
[6]
Daling JR(2003)Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial Lancet 362 95-102
[7]
Claus EB(2010)Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial Lancet Oncol 361 70266-70267
[8]
Stowe M(2006)Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial Jama 295 2727-2741
[9]
Carter D(2011)Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS J Natl Cancer Inst 103 478-488
[10]
Holford T(2012)Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24 J Clin Oncol 30 1268-1273